The latent membrane protein-1 (LMP1) is an integral membrane molecule expressed by Epstein-Barr virus (EBV) during viral latency and displays properties of a constitutively activated member of the TNF receptor family. LMP1 is required for B-cell or monocyte immortalization induced by EBV and is sufficient to transform rodent fibroblasts. Transforming potential of LMP1 is mediated by its cytoplasmic C-terminal domain, which activates various cellular signaling pathways including NFjB and JNK. In this report, we constructed mutants of LMP1 with preserved membrane spanning domain but mutated in the C-terminal domain and a second truncated C-terminal LMP1 fused to the enhanced green fluorescent protein. This latter mutant, termed LMP1-CT, impairs signaling by ectopic LMP1 as well as endogenous EBVexpressed wild-type (wt) LMP1. In contrast to dominantnegative mutants of LMP1 with preserved membrane spanning domains, LMP1-CT was unable to bind wt LMP1 to form an inactive complex. Its dominant-negative effects were due to binding and sequestration of LMP1 adapters TRAF2 and TRADD as assessed by coimmunoprecipitation experiments and confocal analysis. The effect was selective since LMP1-CT did not inhibit IL1b-induced signaling, whereas it impaired TNF-triggered NFjB and JNK signals without affecting TNF-induced apoptosis. In addition and in contrast to LMP1 constructs with membrane localization, LMP-CT did not display cytostatic properties in noninfected cells. Importantly, LMP1-CT inhibited survival induced by LMP1 in an EBV-transformed T-cell line expressing the type II viral latency commonly found in the majority of EBVassociated human tumors. These data demonstrate that LMP1-CT is a new tool to explore the differences between LMP1 and TNF signaling and may facilitate the design of molecules with potential therapeutic roles.
Introduction
Epstein-Barr virus (EBV), the etiological agent of infectious mononucleosis, is a human herpesvirus involved in the development of several human malignancies. EBV expression is tightly associated with the transformed status of infected B lymphocytes and epithelial cells in B lymphomas and carcinomas, and is also observed in some T lymphomas (Rickinson and Kieff, 1996) . In vitro, EBV can infect and immortalize resting B cells to yield permanent growth of lymphoid cell lines (LCLs) (Kaye et al., 1993) . We previously showed that it could also infect and transform T cells and monocytes (Groux et al., 1997; Masy et al., 2002) . In transformed cells, EBV is found in a latent state and only few viral genes are expressed. Nine genes are expressed in LCLs displaying a type III latency, whereas a type II latency restricted to expression of three genes is encountered in EBV-transformed T cells and monocytes (Groux et al., 1997; Masy et al., 2002) . This last transcription pattern is typically found in most of the EBV-associated malignancies. The product of one of these genes is latent membrane protein-1 (LMP1), which has been shown to be essential for B-cell immortalization (Kaye et al., 1993) . In addition, we recently showed that LMP1 is essential for the proliferation of monocytes transformed by EBV (Masy et al., 2002) . LMP1 can be regarded as an oncogene per se since it can transform rodent fibroblasts (Wang et al., 1985) and sensitizes transgenic mice to lymphomas (Kulwichit et al., 1998) .
LMP1 is a 63 kDa plasma membrane protein with six transmembrane segments, which mimics a constitutively activated cell surface receptor of the tumor necrosis factor (TNF) superfamily (Eliopoulos et al., 2001) . Spontaneous oligomerization mediated by transmembrane and cytoplasmic N-terminal fragments induces activation of several signaling pathways (Liebowitz et al., 1986) . Three signaling domains have been identified so far in the cytoplasmic C-terminal region of the protein Gires et al., 1999) . These domains named CTAR1 (for C-terminal activating region 1), CTAR2 or CTAR3 bind various adapters and induce specific signaling pathways. Both CTAR1 and CTAR2 bind TNF receptor-associated factors (TRAFs), either directly in the case of CTAR1 (Devergne et al., 1996 (Devergne et al., , 1998 or indirectly for CTAR2 through binding of the TNF receptor-associated death domain (TRADD) . CTAR2 was also shown to interact with RIP (Izumi et al., 1999) , another adapter of the TNF receptor. CTAR1 and CTAR2 both activate NFkB and p38 kinase pathways (Laherty et al., 1992; Eliopoulos and Young, 1999) . In addition, LMP1 is able to activate the Jun N-terminal kinase (JNK) pathway through the CTAR2 domain (Eliopoulos and Young, 1998) . Activation of these different signaling pathways results in the overexpression of LMP1 target genes including various antiapoptotic genes such as bcl-2, A20, mcl-1, and blf-1, (Henderson et al., 1991; Laherty et al., 1992; Wang et al., 1996) . Other upregulated genes encode for the intercellular adhesion molecules LFA-3 and ICAM-1 (CD54) (Rowe et al., 1995; Gregory et al., 1988) . The signal transduction pathways initiated by CTAR1 and CTAR2 are both essential to B-cell immortalization and cellular transformation. In contrast, CTAR3 was described as a less well-defined domain that can bind Janus activating tyrosine kinase 3 (JAK3) and activate the JAK-STAT pathway by increasing the DNA binding of signal transducing and transcription factor 1 (STAT1) (Gires et al., 1999) . However, until now, no function has been ascribed to the LMP1-triggered JAK-STAT pathway and the role of the CTAR3 domain in this activation has recently been questioned (Higuchi et al., 2002) . Critical residues in CTAR1 and CTAR2 responsible for the binding of adapters, as well as for some signaling and transforming properties have been identified by mutational/deletional analysis. By this approach, shorter domains named transforming effector site (TES) 1 and TES2 have been identified in CTAR1 and CTAR2 respectively (Devergne et al., 1996; Brodeur et al., 1997; Floettmann and Rowe, 1997; .
LMP1 mutants were very useful in many approaches to accumulate data on LMP1 domains, cellular adapters and signaling pathways implicated in LMP1-mediated transformation. One approach conceptually less employed was the use of mutants of LMP1 in their putative dominant-negative functions. Only one study described the powerful effects of such a construct mutated in its signaling domains but preserved in its transmembrane domains (Brennan et al., 2001) . Hence, to get further insight into the role of LMP1 in cellular transformation of EBV-infected cells using this approach, we have constructed a series of LMP1-derived constructs and compared their potential dominant-negative effects. One of them, named LMP1-CT, encodes a protein in which the cytoplasmic C-terminal tail of LMP1 was fused to the enhanced green fluorescent protein (GFP). We compared LMP1-CT action with other membrane constructs like LMP1-TM (a transmembrane mutant of LMP1 deleted of the cytoplasmic C-terminal region), and LMP1-DM (a double mutant TES1m-TES2m where critical residues P 204 XQ 206 XT 208 in TES1 were replaced by Ala (A 204 XA 206 XA 208 ) and the terminal residues of TES2 YYD 386 were deleted). LMP1-CT, LMP1-TM and LMP1-DM were all unable to activate the LMP1 signaling pathways and displayed dominantnegative properties. However, in contrast to LMP1 mutants with preserved membrane localization like LMP1-DM, LMP1-CT had no cytostatic effects on uninfected cells. In addition, our results indicated that LMP1-CT could inhibit not only LMP1 signaling but also intracellular signals generated by other liganddependent receptors, like the TNF receptor, which shares the TRAF2 and TRADD adapters with LMP1. More importantly, LMP1-CT impaired survival of an EBV-transformed cell line through inhibition of the signal triggered by the endogenously expressed LMP1. Our study focused on the mechanisms of action of this novel LMP1 dominant negative and we discussed its potential therapeutic role.
Results

Design and expression of LMP1 mutants
In order to study the role of the LMP1 signaling pathway in EBV-infected cells, we created several mutants with potential dominant-negative effects. Two of them were HA-tagged LMP1 versions, either mutated in critical residues in TES1 and TES2 (LMP1-DM), or containing a deletion in of the C-terminal cytoplasmic tail (LMP1-TM). Another form of LMP1 named LMP1-CT was generated by fusion of the C-terminal cytoplasmic tail of LMP1 with GFP. The mutants used, as well as their predicted subcellular localization, are schematically depicted in Figure 1a . All the constructs were introduced into a pSG5-derived expression vector and were transiently transfected into HEK 293 human epithelial cells. Their expression was analysed by Western blotting (Figure 1b) . As expected, LMP1-DM and wt LMP1 proteins have the same molecular weight (65 kDa), whereas LMP1-TM migrate at 23 kDa, and LMP1-CT exhibits a molecular weight of 72 kDa.
To characterize these mutants, we evaluated their ability to activate LMP1 signaling pathways. HEK 293 cells were cotransfected with increasing amounts of an expression vector encoding wt LMP1 or LMP1-CT together with luciferase reporter constructs for testing NFkB or JNK signaling pathways. Transactivation assays were performed using a kB-luciferase reporter for NFkB and a GAL4/Jun reporter system for JNK. Increasing concentrations of expression vectors of LMP1 strongly enhanced the NFkB pathway, whereas LMP1-CT was unable to activate this pathway (Figure 2a) . Similarly, wt LMP1 but not LMP1-CT activated the JNK pathway (Figure 2b ). In the same manner, neither LMP1-TM nor LMP1-DM was able to activate these both pathways (data not shown). Western blot analysis performed with an anti-LMP1 antibody (S12) showed that similar and increasing levels of wt LMP1 and LMP1-CT proteins were expressed in the transfected cells (Figure 2c ).
LMP1-CT and LMP1-TM have a dominant-negative effect on LMP1-induced signaling pathways Brennan et al. (2001) previously described the dominant-negative effect on LMP1 signaling of LMP1 AAAG mutated in its signaling domains. So, we wanted to test whether LMP1-CT, lacking the transmembrane domains and signaling properties in spite of preserved signaling domains, was also able to inhibit the wt LMP1-mediated activation. To this end, we performed cotransfection experiments using the reporter vectors previously described. As shown in Figure 3a , the strong NFkB activation (600-fold) induced by wt LMP1 overexpression, was abolished by coexpression of LMP1-DM, but also by LMP1-TM and LMP1-CT. Similar results were obtained with the JNK pathway as shown in Figure 3b . As a control of specificity, an LMP1-CT construct mutated in TES1 and TES2 lose these inhibiting properties (data not shown). Thus, LMP1-CT and LMP1-TM act as dominant-negative molecules with the same efficiency that LMP1-DM, a mutant conceptually similar to LMP1 AAAG . LMP1-CT, LMP1-TM and LMP1-DM inhibit induction of endogenous ICAM-1 by ectopic expression of LMP1
As a first approach to demonstrate that blockade of LMP1 signaling properties by LMP1-CT and LMP1-TM could result in physiological outputs in the cells, we analysed the effect of these mutants on induction of an endogenous target gene (ICAM-1/CD54) by wt LMP1. HEK 293 cells were cotransfected with expression vectors coding wt LMP1, LMP1-DM, LMP1-TM or After 48 h, ICAM-1 expression in green fluorescent cells was determined by flow cytometry using phycoerythrin (PE)-conjugated anti-ICAM-1 antibodies. The increase of ICAM-1 expression after wt LMP1 transfection is apparent in the profiles shown on Figure 4a . Expression of LMP1 increased the mean fluorescence intensity of ICAM-1 detection compared to empty control vector. As expected, cotransfection of LMP1 with LMP1-DM, LMP1-TM or LMP1-CT impaired this increase (Figure 4b ).
LMP1-CT inhibits signaling mediated by TRAF2 and TRADD
It has previously been demonstrated that the inhibitory action of LMP1 AAAG on wt LMP1 signaling is due to the formation of nonfunctional complexes through oligomerization of mutated and WT proteins at the cellular membrane (Brennan et al., 2001 ). To check formation of possible LMP1/LMP1-CT complexes, coimmunoprecipitation experiments were performed. HEK 293 cells were transfected with vectors coding wt LMP1 and/or LMP1-CT. Cells were lysed 48 h after transfection and samples were examined by Western blotting using LMP1 antibodies, with or without prior immunoprecipitation with an anti-GFP antibody. Direct immunoblotting shows expression of both LMP1 and LMP1-CT ( Figure 5 ). When immunoblotting was preceded by immunoprecipitation with an anti-GFP antibody, the presence of LMP1 was not detected. Similar experiments performed with LMP1-TM showed that this mutant binds wt LMP1 (data not shown). These results clearly indicate that LMP1-CT is unable to bind wt LMP1, and that its action is not mediated by the formation of inactive complexes. We next investigated the role played by TRAF2 and TRADD that mediate LMP1 signaling through binding to the C-terminal part of active LMP1 complexes. In contrast, TRAF6 do not bind directly to LMP1 but is able to bind the interleukin 1 receptor (IL-1R) and mediate the activation of NFkB by this cytokine. TRAF2, TRADD or TRAF6 are all inducers of NFkB when overexpressed in the cells. We have tested the effects of LMP1-CT and LMP1-TM on NFkB activity induced by these adapter molecules. Results shown in Figure 6 confirmed that TRAF2, TRADD or TRAF6 transiently expressed in HEK 293 cells duly induced NFkB. As anticipated from its mechanistic action, LMP1-TM is unable to modulate the NFkB activity induced by these three mediators ( Figure 6 ). In contrast, LMP1-CT inhibited the NFkB activity induced by TRAF2 and TRADD, whereas it did not impair NFkB activity induced by TRAF6 ( Figure 6 ).
LMP1-CT hampers the recruitment of TRAF2 and TRADD by LMP1
The selective interference of TRAF2 and TRADD adapter-triggered NFkB activation suggests that LMP1-CT could fulfill its inhibitory action through binding to TRAF2 and TRADD. To test the ability of LMP1-CT to bind endogenous TRAF2 and TRADD proteins, we performed coimmunoprecipitation experiments on transfected cells. wt LMP1 and LMP1-CT were transfected alone or cotransfected into HEK 293 cells. After 48 h, cells were harvested, lysates immunoprecipitated with an anti-TRADD or anti-TRAF2 antibodies and immunoprecipitates were analysed in Western blotting experiments. Western-blot analysis performed with an S12 antibody (anti-LMP1) after TRADD immunoprecipitation reveals that LMP1-CT and wt LMP1 were able to bind TRADD (Figure 7a ). Importantly, after cotransfection of LMP1-CT and wt LMP1, only LMP1-CT was detected in TRADD immunoprecipitates indicating that LMP1-CT hampers the recruitment of TRADD to wt LMP1. Similar results were obtained for TRAF2 coimmunoprecipitation assays; that is, LMP1-CT bound TRAF2, and Coimmunoprecipitation experiments were performed to test the ability of LMP1-CT to bind LMP1. Western blot analysis using S12 antibodies was performed with or without prior immunoprecipitation with an anti-GFP antibody. LMP1 migrates at 65 kDa (white arrow) whereas LMP1-CT migrates at 72 kDa (arrowhead) and exhibited a cleavage form (star). The results show that LMP1 is never associated with GFP immunoprecipitates Mutant of LMP1 differentially affects LMP1 and TNF signaling E Adriaenssens et al prevented the binding of TRAF2 to wt LMP1 (Figure 7b ). The use of LMP1-CT-DM, mutated in TRAF and TRADD binding domains, assessed the specificity of this inhibition. Indeed, as shown for TRAF2 in Figure 7c , this mutant fails to associate with these adaptor proteins. This lack of interaction was reflected in the reduced inhibitory properties displayed by this mutant on LMP1 signaling (data not shown). These results were confirmed by confocal microscopy analysis. In cells transfected with LMP1-CT, both the mutant and TRAF2 remain mainly cytoplasmic ( Figure 7d ). As expected for a direct interaction of LMP1-CT and TRAF2 in the cytoplasm of transfected cells, their signals colocalized (Figure 7d , merge panel). Our wt LMP1 was not fused to GFP. So, we used cotransfection of this construct with GFP to identify the transfected cells and to compare to experiments with GFP-tagged LMP1-CT. In control cells transfected with GFP alone, endogenous TRAF2 was detected throughout the cytoplasm, as expected (Figure 8 , upper row). In cells cotransfected with wt LMP1 and GFP vectors, the majority of TRAF2 was located at the plasma membrane in form of clusters as a consequence of LMP1 recruitment (Figure 8 , middle row). This recruitment of TRAF2 to wt LMP1 membrane complexes was impeded in cotransfection assays of wt LMP1 with LMP1-CT (Figure 8 , lower row). This is assessed by the similar cytoplasmic distribution of the TRAF2 signal whether the cell was transfected or not and by the colocalization of the GFP (LMP1-CT) and TRAF2 signals in the transfected cell (merge panel). Similar results were obtained from confocal microscopy analysis of TRADD localization (data not shown).
LMP1-CT action is specific for TRAF2-and selected TRADD-dependent signaling pathways
Since LMP1-CT seemed to inhibit signaling downstream of TRADD and TRAF2, we tested its potential action on signaling by cytokines receptors that use these adapter molecules or related mediators. Upon TNF binding, its receptors (TNFRI and TNFRII) recruit TRADD and/or TRAF2 in their signaling complexes. In contrast, interleukin 1b (IL-1b)-triggered signal Coimmunoprecipitation experiments were performed 48 h after, to test the ability of LMP1-CT to bind TRADD and TRAF2. Western blot analyses using an anti-LMP1 antibody (S12) was performed prior or after immunoprecipitation with anti-TRADD (a) or anti-TRAF2 (b) antibodies. Co immunoprecipitation experiments were performed with 1 mg of protein, and 2 mg of whole-cell lysate was used for Western blotting. LMP1 is indicated by a white arrow and LMP1-CT with an arrowhead (the star indicates a cleavage form). The results show that LMP1-CT binds TRADD and TRAF2. LMP1-CT impairs the association between LMP1 and its adapters. Western blot analyses after immunoprecipitations were performed to assess that similar quantities of TRAF2 and TRADD were engaged. (c) Specificity of this inhibition was assessed by using a mutated form of LMP1-CT. LMP1-CT-DM is mutated in TES1 and TES2 regions and is unable to bind TRAF2. Figure 9a shows dose-dependent response to TNF in HEK 293 cells of a NFkB luciferase reporter cotransfected with LMP1-CT, LMP1-TM or an empty vector. As expected, TNF highly increased the NFkB activity in cells (up to 50-fold) and this activation was not impeded by cotransfection of LMP1-TM. In contrast, in cells cotransfected with LMP1-CT, TNF was unable to efficiently activate the NFkB pathway.
Similar experiments were performed with IL-1b treatment. In this case, neither LMP1-CT nor LMP1-TM was able to inhibit the NFkB activation induced by IL-1b (Figure 9b ). These experiments confirmed that, whereas LMP1-TM restricted its inhibitory effects to LMP1 signaling, LMP1-CT could inhibit signaling pathways of other receptors acting through TRADD or TRAF2 mediators.
In order to evaluate the consequences of inhibition on the biological outputs of TNF signaling, we explored the action of LMP1-CT on TNF-induced apoptosis in HEK 293 cells. We transfected empty vector, LMP1-CT or TRAF2 dominant negative (DN) as positive control, together with a GFP vector when necessary. Apoptosis and cell cycle were monitored on GFP-positive cells by flow cytometry, after propidium iodine incorporation (Figure 9c ). In mock-transfected cells, TNF is unable to induce a significant increase in apoptosis. In contrast, in LMP1-CT-transfected cells, TNF increases the population of cells in sub-G0 phase, probably by increasing apoptosis. In TRAF2-DN-transfected cells, TNF is also able to increase apoptosis, even if the basal level of apoptosis is relatively high (about 30%). Accordingly, these data show that LMP1-CT acts similarly to a TRAF2 dominant negative on TNFinduced apoptosis. 
LMP1-CT downregulates expression of ICAM-1 and impairs LMP1-dependent survival in EBV-transformed cells
The inhibiting properties exhibited by LMP1-CT prompted us to investigate its capacities in challenging signaling and phenotypes associated to LMP1 in EBVtransformed cells. We first asked whether LMP1-CT was able to modulate ICAM-1 expression in EBV-infected cells. To this aim, a T-cell line infected by EBV (NC5) or uninfected T cells (Jurkat) were electroporated with LMP1-CT, LMP1-TM, wt LMP1 or empty vector together with a pEGFP-C1 reporter vector. After 48 h, the cells were stained with PE-conjugated anti-CD54 antibodies and analysed by two-color flow cytometry. Figure 10a shows the mean fluorescence intensity of ICAM-1 staining in NC5 and Jurkat GFP-positive cells transfected with different forms of LMP1. In Jurkat cells (EBV-negative), wt LMP1 increased the ICAM-1 expression at the cellular surface, whereas LMP1-CT or LMP1-TM has no effect as expected. In NC5 cells (EBV-positive), both LMP1-CT and LMP1-TM inhibited ICAM-1 expression, as compared with control, probably by interfering with the endogenous LMP1 signaling. Furthermore, exogenous wt LMP1 is able to increase the basal level of ICAM-1 expression. These results demonstrate that LMP1-CT as LMP1-TM can inhibit endogenous gene induction by wt LMP1 in EBVinfected cells.
LMP1 is critical for survival of LCLs exhibiting type III latency (Kaye et al., 1993) . We previously showed that it could also be essential for an EBV-transformed monocyte expressing a type II latency (Masy et al., 2002) . To study the potential role of LMP1-CT on cell survival induced by LMP1, we have transfected by electroporation this mutant in LCLs but also into the EBV-infected T-cell line NC5, exhibiting type II latency. Apoptosis and cell cycle were monitored by flow cytometry, after propidium iodine incorporation ( Figure  10b ). In the case of NC5, about 33% of these cells were in sub-G0, after transfection. This large amount of cells in sub-G0 was probably due to stress caused by drastic conditions of electroporation. In cells transfected with LMP1-CT 71% of cells exhibit DNA content in sub-G0. In addition, cell cycle of LMP1-CT-transfected cells was strongly affected when compared with empty vectortransfected cells. Similar results were obtained for LCLs (data not shown). These data demonstrated that inhibition of LMP1 signaling by LMP1-CT impairs survival of EBV-transformed cells. In addition, we confirm that in EBV-infected cells exhibiting a type II latency, LMP1 is essential to cell growth.
LMP1-CT did not display inhibiting side effects on growth of uninfected cells
Owing to membrane localization, wt LMP1 and all LMP1-derived constructs with preserved transmembrane domains were reported to display cytostatic effects on uninfected cells (Kaykas and Sugden, 2000; Coffin et al., 2003) . This side effect could be a major drawback in analysing the dominant-negative properties of certain LMP1-derived peptides and for their potential use in therapies. So, to address this point for the LMP1 mutants described in this work, we performed cellular growth assays of HEK 293 cells transiently transfected with the different constructs. As expected from published data (Kaykas and Sugden, 2000; Coffin et al., 2003) , cells transfected with wt LMP or LMP1-DM were impaired in their growth potential when compared to mock-transfected cells (Figure 10c ). This was also the case for LMP1-TM-transfected cells (data not shown). By contrast, cells transfected with LMP1-CT display a cellular growth similar to control cells (Figure 10c) . Thus, LMP1-CT did not exhibit the unspecific cytostatic properties displayed by the other dominant-negative mutants. This result probably highlights the phenotypic consequences of very different modes of action
Discussion
This study demonstrated that LMP1-CT, LMP1-TM and LMP1-DM act as dominant-negative mutants inhibiting all transduction pathways induced by the oncogenic protein LMP1. Indeed, they are per se unable to activate NFkB and JNK pathways, but impair activation induced by wt LMP1. Efficiency of the inhibition was assessed by transactivation reporter assays, colocalization and coimmunoprecipitation of LMP1 with endogenous adapters and analysis of endogenous protein expression induced by LMP1. Moreover, this inhibition results in cell death in different EBV-transformed cell lines. We further demonstrated that, in contrast to LMP1-TM, LMP1-CT is unable to bind wt LMP1, whereas it selectively sequesters and inactivates signaling molecules in the cytoplasm. This is reflected in the selective impairment of TNF-evoked NFkB signaling by LMP1-CT whereas it favors TNFtriggered cell death. As reported for LMP1 AAAG (Brennan et al., 2001 ), LMP1-TM and LMP1-DM act as dominant-negative mutants by forming with wt LMP1 inactive complexes at the membrane unable to recruit adapters. This indicates that these mutants are specific to LMP1. These two mutants show the same efficiency of LMP1 inhibition. However, as reported by others for similar mutants, they show a nonspecific cytostatic effect mediated by their transmembrane domains (Kaykas and Sugden, 2000; Coffin et al., 2003) .
Accumulating data indicate that members of the TNFR family must fulfill two prerequisites for signaling: specific membrane localization and trimerization of their cytoplasmic signaling domains (Wallach et al., 1999) . This results in recruitment of adapters for signaling. The lack of these prerequisites could explain impaired signaling as a result of the lack of interaction between cytoplasmic and/or monomeric signaling domains and adapters. As reported by others for a LMP1 signaling domain devoid of membrane anchoring, LMP1-CT is cytoplasmic and unable, upon overexpression, to trigger the LMP1-dependent signaling pathways (Kaykas et al., 2001) . In this respect, it behaves like the corresponding mutants of other members of the TNFR family, including CD40 (Kaykas et al., 2001; Werneburg et al., 2001) . We demonstrated here that LMP1-CT, a monomeric form of the cytoplasmic tail of LMP1, could readily be coimmunoprecipitated with TRADD and TRAF2. Thus, our work showed that the cytoplasmic tail of LMP1 is sufficient to bind TRADD and TRAF2 in the absence of the membrane component. This indicates that transmembrane domains of LMP1 are not necessary for interaction with these adapters. In addition, our results show that binding of TRADD and TRAF2 to LMP1 is possible without trimerization of the viral receptor since no domains allowing oligomerization are present in our mutant. The TRAF2 and TRADD binding properties of LMP1-CT are in apparent contradiction with the behavior of another recently described LMP1 monomeric mutant. This mutant devoid of transmembrane domains 3-6 preserves its membrane localization and part of NFkB signaling but is unable to bind TRADD, TRAF1, 2 and 3 (Coffin et al., 2003) . The authors explain the lack of interaction between mutated LMP1 and adapters by a nonoligomerization. Since our results show that oligomerization is not require for LMP1 binding to adapters, we rather favor difference in subcellular localization of these molecules to explain their opposite behaviors.
In fact, recent studies indicate that activated receptors of the TNFR family were accumulated as oligomers in subdomains of the cytoplasmic membrane component termed lipid RAFTs (Hueber, 2003) . Likewise, recent studies showed that enforced LMP1 recruitment into lipid rafts is essential and sufficient to promote signaling, whereas the role of the trimerization of this protein is a matter of debate (Kaykas et al., 2001) . Indeed, these authors show that a cytoplasmic trimerized LMP1 cytoplasmic domain is inefficient in signaling, whereas trimerization of the corresponding cytoplasmic domain of CD40 preserves part of its signaling properties. This discrepancy between two functionally related receptors is not due to a lack of interaction with adapters (our results and Werneburg et al., 2001) . Our data bring some clues to the apparent dispensability of trimerization when LMP1 is artificially targeted to lipid RAFTs. Owing to the trimeric form of preformed adapter complexes (McWhirter et al., 1999; Park et al., 1999) , this opens the interesting possibility of a more driving role of TRAF2 and TRADD in signaling complexes as part of a kind of nucleation process.
In contrast to LMP1 mutants with preserved membrane localization, we show that LMP1-CT is unable to bind wt LMP1 (our results and Brennan et al., 2001) . Hence, the trans-dominant inhibitory effects of LMP1-CT are not due to the formation of inactive complexes at the plasma membrane. Considering its adapter binding properties, it is likely that LMP1-CT hampers the recruitment of TRADD and TRAF2 by LMP1, by its direct binding to these signaling molecules.
Importantly, LMP1-CT inhibits signals induced by overexpression of TRAF2 or TRADD. Activation of transduction pathways by overexpression of adapters is not well understood but seems not to require the crucial step of membrane recruitment (Baud et al., 1999) . Binding of these overexpressed adapters to LMP1-CT likely impairs binding of other critical downstream molecules involved in signaling. For example, TRAF interaction domains of receptors are shared with downstream effectors or modulators of the TRAF2 activity, like TANK/I-TRAF (Cheng and Baltimore, 1996) . This is also clearly the case for TRADD, which needs TRAF2 for downstream NFkB signaling, since the TRADD and receptor interaction domains at the TRAF2 surface overlap (Park et al., 2000; Tsao et al., 2000) . Hence, direct binding of TRAF2 to TRADD and TRAF-interacting domains of receptors are mutually exclusive. So, overexpression of LMP1-CT could hamper binding of TRAF2 to TRADD through binding of TRAF2 by its CTAR1 domain. This should result in downregulation of TRADD-dependent signal outputs. The specificity and selectivity of LMP1-CT in inhibiting signaling molecules is exemplified by the lack of inhibition of TRAF6, a far downstream effector that does not interact directly with LMP1. Indeed, TRAF6, which was reported to be indirectly recruited to CTAR2 in LMP1-triggered P38 signaling (Schultheiss et al., 2001) , most likely escapes interaction and ensuing inhibition by LMP1-CT.
These specificity and selectivity of LMP1-CT were confirmed by studying IL-1 and TNF receptor signaling. Indeed, to transduce signaling pathways, the TNF receptor mainly requires TRAF2 and TRADD, whereas the IL-1 receptor rather engages TRAF6 (Baud et al., 1999) . Then, we have shown that LMP1-CT inhibits activation of the NFkB pathway induced by TNF, whereas no change was observed on NFkB activation induced by IL-1. In addition to NFkB induction through TRAF2 recruitment to TNFR1 upon activation, TRADD also mediates TNF-triggered apoptosis through recruitment of FADD and caspases to the receptor. Thus, the two TNFR1-TRADD signaling cascades bifurcate at the TRADD level (Hsu et al., 1996) . However, in contrast to its action of NFkB activation and in spite of its interaction with TRADD, LMP1-CT was inefficient in inhibiting the proapoptotic function of TNF. This could be explained by the use of different domains of TRADD for the two pathways. The C-terminal Death Domain of TRADD interacts with TNFR1 and FADD, whereas N-terminal region interacts with TRAF2 (Hsu et al., 1996) . The LMP1 CTAR2 region was shown to interact also with the Nterminal region of TRADD (Izumi et al., 1999; Kieser et al., 1999) . Thus, LMP1-CT binding to TRADD keeps its Death Domain free to be recruited by TNFR1 and to interact with FADD in order to trigger apoptosis. In this respect, LMP1-CT displays the same inhibitory specificity as a previously reported TRAF2 dominantnegative mutant (Hsu et al., 1996) .
Beyond its inhibitory properties on LMP1 signaling and as a consequence of it, we showed that LMP1-CT was able to dampen the proliferation of EBV-transformed cells. This is the case for LCLs, the wellestablished model of B-cell infection and transformation by EBV exhibiting a type III latency, but also for NC5 an in vitro transformed T-cell line, which displays a type II latency (Groux et al., 1997) . This result and our recently published data on a monocytic cell line (Masy et al., 2002) , extend the number of cellular models to study LMP1-dependent transformation by EBV to cells displaying type II viral latency.
EBV infection is correlated with several malignancies development (Rickinson and Kieff, 1996) . As LMP1 is known as a main oncogenic protein of EBV, the inhibition of this oncogene could be of major importance in different pathologies. It is notably the case in T lymphomas, post-transplantation lymphoproliferative disorders (PTLD), and some carcinomas such as nasopharyngeal carcinomas. In these pathologies, inhibition of LMP1 can contribute to reducing cancerous development. Characterization of molecules with potent inhibitory action on LMP1 signaling is of great interest in therapeutics. In this respect, inhibitory domains derived from the cytoplasmic part of LMP1 could represent more valuable tools than mutants with membrane localization. Indeed, we confirmed with LMP1-TM and LMP1-DM that transmembrane domains confer nonspecific cytostatic side effects to LMP1 constructs localized at the membrane (Kaykas and Sugden, 2000; Coffin et al., 2003) . Our results show that this was not the case for LMP1-CT. In terms of secondary effects on nonmalignant cells, this could provide an advantage to this mutant when compared to other dominant-negative mutants such as LMP1-TM and LMP1-DM.
Moreover, an inhibitor like LMP1-CT or derivatives targeting downstream signaling molecules could be very useful in tumors with a constitutively activated signaling pathway but lacking LMP1 or EBV expression. In Hodgkin's disease lymphomas for example, the tumors display constitutive NFkB activation whether or not they express EBV genes (Horie et al., 2002b) . This is probably due to an autocrine activation loop involving receptors of the TNFR family like CD30 and constitutive oligomerization of activated TRAF molecules (Horie et al., 2002a) . LMP1-CT-based inhibitors should inhibit these constitutively activated pathways. Accordingly, a LMP1-derived construct able to bind and deplete TRAF2 and TRADD adapters could be used in all pathologies implicating TNF. Indeed, overexpression of this factor is responsible for some diseases, such as autoimmune disorders (rheumatoid polyarthritis, hemophagocytic syndrome), toxic shock, and others (Aggarwal, 2003) . The selective action on activation versus apoptotic properties of TNF emphasizes the interest of this kind of construct.
In summary, this study characterized a novel dominant-negative form of LMP1. This construct may allow further elucidation of the biochemical events that constitute the signaling pathways of LMP1, but also of all receptors of the TNFR family using the same adapters. TRAF2 and TRADD recruitment of LMP1 are the primary events that mediate activation of IKKs, JNK and P38 kinases. An inhibitor of this recruitment may contribute to the study of signaling pathways as well as the genes targeted by LMP1 and this inhibitor or derivatives may have useful therapeutic applications.
Materials and methods
Cell culture
HEK 293, a human embryonic kidney cell line, was obtained from the American Type Culture Collection (ATCC) (CRL 1573) and grown in Dulbeco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). Jurkat is a cell line derived from an EBV negative T cell lymphoma and NC5 is an EBV-transformed T cell line obtained after infection of PBMC by B95.8 supernatant (Groux et al., 1997) . Both cell types were propagated in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 200 U/ml penicillin, and 200 mg/ml streptomycin. All cells were maintained at 371C in a humidified atmosphere with 5% CO 2 .
Constructs
We used a pSG5 (Stratagene) derived plasmid containing an HA epitope in front of the multicloning site (generous gift of JL Baert). pSV-HA-LMP1 was obtained after cloning of the wt LMP1 cDNA derived from the B95.8 strain of EBV. HA-LMP1 was under the control of the SV-40 promoter of the pSG5 vector. pSV-HA-LMP1-TM (named LMP1-TM for transmembrane domains) encodes an LMP1 protein missing the last 199 amino acids. pSV-HA-LMP1-DM mutant (named LMP1-DM for LMP1 double mutant) was generated by sitedirected mutagenesis. The codons 204-208 were mutated from PXQXT to AXAXA and the codons 384-386 end-terminal YYD were deleted. The LMP1-CT construct was performed using pEGFP-C1 (clontech), in which the C-terminal region (the last 187 amino acids) of LMP1 was fused with GFP. An LMP1-CT-DM construct in which TES1 and TES2 regions were mutated was used as control. The TRADD, TRAF2, and TRAF6 expression vectors were a generous gift of M Rothe (Tularik). The TRAF2-DN expression plasmid was a generous gift of P Mehlen (Ye et al., 1999) . The reporter plasmids used in this study were as follows: the NFkB luciferase reporter construct containing five NFkB responsive element in tandem was from Stratagene. The Gal4-luc, Gal4-jun heterologous vectors were a generous gift of B Derijard and M Ptashne.
Transient transfection
For transient expression experiments in HEK 293 cells, 3 Â 10 5 cells were seeded in six-well dish. Cotransfections were performed using polyethylenimine reagent (PEI, Euromedex) in OptiMEM (Gibco, BRL). Routinely, 0.2 mg of reporter constructs were cotransfected with 1 mg of inducer vectors. In case of dose effect, the amount of DNA was completed with empty vector (pEGFP-C1 for LMP1-CT and pSV-HA for other LMP1 derivative constructs). Cells were incubated with reagents 5 h at 371C, then the culture medium was replaced by fresh medium with serum for 48 h. For ICAM-1 assays, Western blot and immunoprecipitation experiments no reporter construct were added.
For transient expression of LMP1 derivative vectors in a suspension culture, 1 Â 10 7 cells were transfected by electroporation using a Bio-Rad Genepulser II electroporator at 250 V and 950 mF on ice in 500 ml of medium without serum. After 10 min, cells were seeded in 5 ml of fresh growth medium and were then incubated under normal conditions.
Luciferase activity and ICAM-1 assays
To measure the reporter activity, cells were harvested 48 h after transfections, with a reporter lysis buffer (Promega). The lysates were clarified by centrifugation, Luc assay was performed using a Luciferase assay system (Promega) and Luc activities were measured by a lumat LB 9501 (Berthold). Triplicate samples were performed in each experiment, and standard deviations (s.d.) are shown. Each experiment was repeated at least twice with independent plasmid preparations to assess reproducibility.
The induction of ICAM-1/CD54 protein in transfected cells was assayed by immunofluorescence staining of viable cells, followed by flow cytometry using an EPICS-XL cytometer (Coulter). Briefly, 48 h post-transfection cells were washed and stained with a PE-conjugated monoclonal antibody to human CD54 (Immunotech-Coulter) at 41C for 60 min. ICAM-1/ CD54 expression was analysed by flow cytometry in GFPpositive cells.
Immunoprecipitations and Western blotting
For immunoprecipitations, 1 Â 10 6 HEK 293 cells were transfected with plasmid DNA according to the protocol described above. At 48 h post-transfection, 293 cells were washed twice with phosphate-buffered saline (PBS), then lysed 15 min on ice in 500 ml of lysis buffer (20 mM Tris-HCl pH 7.4, 50 mM NaCl, 5 mM EDTA, 1% Triton X-100) to which 1 mM PMSF, 1 mM leupeptine, 1 mM sodium orthovanadate and 5 IU/ml aprotinine had been added prior to use. The lysates were clarified by centrifugation (14 000 r.p.m. for 15 min), and the supernatant was incubated under gentle agitation with primary antibody (anti-TRAF2 rabbit polyclonal IgG (sc-876) or anti-TRADD goat polyclonal IgG (sc-1163) Santa Cruz or mouse monoclonal anti-LMP1 antibody (S12) gift of P Busson) for 1 h at 41C. Then, Protein A-Sepharose beads (Amersham Pharmacia) were added, 1 h at 41C under gentle rotation. Beads were centrifuged 1 min at 14 000 r.p.m., washed four times in PY buffer (20 mM Tris-HCl pH 7.4, 50 mM NaCl, 5 mM EDTA, 0.1% Triton X-100) and eluted by boiling in 30 ml of Laemmli Blue. Eluate was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subjected to Western blotting to detect LMP1.
For Western blotting analysis, cells were washed in PBS and lysed on ice in 500 ml of lysis buffer. The lysates were clarified by centrifugation and were separated by SDS-PAGE (Euromedex). Then, protein was transferred onto membranes (Immobilon-P, Millipore) by electroblotting. Membranes were blocked with 0.2% casein in PBS-0.1% Tween and then incubated with appropriate primary antibodies (anti-TRAF2, anti-TRADD or anti-LMP1 antibodies described above or mouse monoclonal anti-HA (16B12) BAbCO). After several washes in PBS-0.2% Tween, membranes were incubated with peroxidase-conjugated secondary antibodies (Jackson Immunoresearch) and analysed using an ECL kit (Amersham) before autoradiography.
Immunofluorescent labeling and confocal microscopy
Cells, cultured onto glass coverslips coated with collagen, were transfected according to protocols described above with wt LMP1 and pEGFP-C1, LMP1-CT alone or LMP1-CT and wt LMP1. Cells were washed and fixed with 4% paraformaldehyde for 30 min at 41C. After washing with PBS/BSA 1 mg/ml, fixation was stopped with ammonium chloride 10 min at room temperature (RT). Cells were permeabilized 10 min with 0.05% saponin in PBS/BSA 1 mg/ml. Cells were then incubated for 1 h at RT, with primary antibody (anti-TRAF2 or anti-TRADD or anti-LMP1 described above). After two washes with permeabilizing buffer, cells were incubated with secondary antibodies (polyclonal goat anti-rabbit IgG or polyclonal donkey anti-goat IgG coupled to Alexa 568, or polyclonal goat anti-mouse IgG coupled to Alexa 488 for detection of TRAF2, TRADD and LMP1 respectively) 30 min at 371C. Cells were washed twice with permeabilizing buffer, once with PBS/BSA 1 mg/ml and then with PBS alone. Slides were mounted using Vectaschield mounting medium (Vector laboratories). Fluorescence-stained slides were examined under a Leica TSC NT laser scanning confocal microscope. A Z-series was performed and equatorial regions are shown.
Viability test
To measure the apoptotic effect of our different constructs, we performed a cell cycle analysis by flow cytometry, after propidium iodine incorporation. Cells transfected with LMP1-CT or TRAF2-DN as a positive control, were fixed in paraformaldehyde (4%, 30 min at 41C), rinsed with PBS, and permeabilized with ethanol (70%, 30 min at RT). Then, cells were incubated with 200 mg/ml of propidium iodine and 200 mg/ml of Rnase A (30 min at 371C) and stored at 41C until use. Cell cycle was analysed by flow cytometry in GFP-positive cells. Experiments were performed on EBVinfected cells NC5, to assess the effect of LMP1-CT on cell cycle and apoptosis. In addition, the same experiments were performed on HEK 293 cells treated or untreated for 6 h with TNF to determinate the role of LMP1-CT on TNF-induced apoptosis.
Cellular growth assay
To determine the nonspecific cytostatic effect of our different mutants, we performed a growth assay after transfection of HEK 293 cells with wt LMP1, LMP1-DM, LMP1-CT or empty vector as control (1 mg each). Cells were counted 24 and 48 h after transfection and results are shown as mean7s.d. values of triplicate experiments.
